Transforming growth factor-beta receptor type II fusion polypeptides
US10316076B2 · kind B2 · utility
2Cited by
26References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2017 |
| Grant date | Jun 11, 2019 |
| Priority date | — |
| Expiry date | Sep 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.